Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults |
| |
Authors: | Lisa A. Jackson Alejandra Gurtman Martin van Cleeff Kathrin U. Jansen Deepthi Jayawardene Carmel Devlin Daniel A. Scott Emilio A. Emini William C. Gruber Beate Schmoele-Thoma |
| |
Affiliation: | 1. Group Health Research Institute, Seattle, Washington, United States;2. Vaccine Research Pfizer Inc, Pearl River, New York, United States;3. Triangle Medical Research Associates, Cary, North Carolina, United States;4. Pfizer GmbH, Berlin, Germany |
| |
Abstract: | BackgroundStreptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States. Pneumococcal conjugate vaccines are efficacious against pneumococcal disease in children and may also offer advantages in adults.MethodsWe performed a randomized, modified double-blind trial that compared a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in 831 pneumococcal vaccine naive adults 60–64 years of age. An additional group of 403 adults 50–59 years of age received open-label PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured at baseline, and at 1 month and 1 year after vaccination.ResultsIn the randomized trial, the month 1 post-vaccination OPA geometric mean titers in the PCV13 group were statistically significantly higher than in the PPSV23 group for 8 of the 12 serotypes common to both vaccines and for serotype 6A, a serotype unique to PCV13, and were comparable for the other 4 common serotypes. The immune response to PCV13 was generally greater in adults 50–59 years of age compared to adults 60–64 years of age. OPA titers declined from 1 month to 1 year after PCV13 administration but remained higher than pre-vaccination baseline titers.ConclusionsPCV13 induces a greater functional immune response than PPSV23 for the majority of serotypes covered by PCV13, suggesting that PCV13 could offer immunological advantages over PPSV23 for prevention of vaccine-type pneumococcal infection. |
| |
Keywords: | AE, adverse event CI, confidence interval CRM197, cross-reactive material 197 GMR, geometric mean ratio GMT, geometric mean titer IPD, invasive pneumococcal disease LLOQ, lower limit of quantitation LOD, limit of detection OPA, opsonophagocytic activity PCV, pneumococcal polysaccharide conjugate vaccine PCV7, 7-valent pneumococcal conjugate vaccine PCV13, 13-valent pneumococcal conjugate vaccine PPSV23, 23-valent polysaccharide vaccine RCDC, reverse cumulative distribution curve SAE, serious adverse event |
本文献已被 ScienceDirect 等数据库收录! |
|